The invention provides disintegrin variants, and more specifically to disintegrin variants which are selective .alpha.v.beta.3 integrin antagonists for treatment and prevention of .alpha.v.beta.3 integrin-associated diseases. The present invention also relates to pegylated proteins, including proteins comprising a disintegrin variant having an RGD motif variant .sup.48ARLDDL.sup.53. The invention also relates to the use of the polypeptides of the invention for the treatment and prevention of .alpha.v.beta.3 integrin-associated diseases.
|Translated title of the contribution||去整合蛋白變異體及其醫藥用途|
|Publication status||Published - 1800|